Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule

Leuk Lymphoma. 2018 Jul;59(7):1722-1725. doi: 10.1080/10428194.2017.1393673. Epub 2017 Oct 30.

Authors

Christine Greil¹, Gabriele Ihorst², Chrissoula Kiote-Schmidt¹, Steffi Hildenbeutel¹, Katja Kühbach¹, Roland Bosse¹, Justus Duyster¹, Monika Engelhardt¹, Ralph Wäsch¹

Affiliations

¹ a Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine , Medical Center - University of Freiburg , Freiburg , Germany.
² b Clinical Trials Unit, Faculty of Medicine , University of Freiburg , Freiburg , Germany.

PMID: 29081261
DOI: 10.1080/10428194.2017.1393673

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Benzylamines
Cell Count
Cost-Benefit Analysis
Cyclams
Hematopoietic Stem Cell Mobilization* / methods
Hematopoietic Stem Cells / cytology
Hematopoietic Stem Cells / metabolism
Heterocyclic Compounds / administration & dosage
Humans
Lymphoma / therapy*
Multiple Myeloma / diagnosis
Multiple Myeloma / therapy*
Peripheral Blood Stem Cell Transplantation* / adverse effects
Peripheral Blood Stem Cell Transplantation* / methods
Treatment Outcome

Substances

Benzylamines
Cyclams
Heterocyclic Compounds
plerixafor